Form 4: Recursion Pharmaceuticals Director Granted Equity Awards Valued at Over $225,000

Recursion Pharmaceuticals, Inc. Director Franziska Michor was granted 22,016 restricted stock units and 44,031 stock options, valued at approximately $225,000 based on the option exercise price, as part of the company's outside director compensation policy.

Summary

• Franziska Michor, a Director at RECURSION PHARMACEUTICALS, INC. (RXRX), was granted equity awards on June 18, 2025.
• The grant included 22,016 Class A Common Stock shares in the form of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0 and will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, contingent on continued service.
• Following this transaction, Ms. Michor beneficially owns 127,053 shares of Class A Common Stock.
• Additionally, Ms. Michor was granted 44,031 stock options with an exercise price of $5.11 per share.
• These stock options were granted at a price of $0 and will vest and become exercisable on the earlier of June 18, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, also subject to continued service.
• The expiration date for these stock options is June 18, 2035.
• After this transaction, Ms. Michor beneficially owns 44,031 stock options.
• The total value of the granted options, if exercised at the strike price, is approximately $225,000 (44,031 options * $5.11/option).

Sentiment

Score: 6

Explanation: The document is a routine disclosure of director compensation, which is generally a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operational performance.

Positives

• The grant of equity awards to a director aligns their interests with those of shareholders, incentivizing long-term performance and commitment to the company.
• The transaction is part of a pre-established 'Outside Director Compensation Policy', indicating a structured and transparent approach to executive compensation.

Negatives

• The issuance of new equity awards, such as RSUs and stock options, can lead to a slight dilution of existing shareholder ownership, although the impact from this specific grant is minimal.

Risks

• The vesting of both RSUs and stock options is subject to the reporting person's continued service to the Issuer, meaning the awards could be forfeited if service ceases before vesting conditions are met.

Future Outlook

The granted Restricted Stock Units and Stock Options are set to vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, contingent on the director's continued service.

Industry Context

This Form 4 filing is a standard disclosure of insider equity compensation, common across all publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where attracting and retaining top talent, including directors, often involves significant equity incentives.

Comparison to Industry Standards

• The grant of equity awards to outside directors is a common practice in the U.S. public company landscape, aligning director incentives with shareholder value creation.
• The structure of RSUs and stock options with service-based vesting is standard for director compensation, similar to practices at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX) which also utilize equity to compensate their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of equity awards to a director is considered a related party transaction, as it involves compensation to an insider of the company.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares upon vesting, but also benefit from increased alignment of director interests with long-term company performance.
• Director (Franziska Michor): Receives significant equity compensation, incentivizing continued service and contribution to the company's success.

Next Steps

• The Restricted Stock Units and Stock Options will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Grant, RECURSION PHARMACEUTICALS, RXRX, Franziska Michor